Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Gemigliptin DDI with Dapagliflozin or Empagliflozin
NCT03565458Phase 1Unknown
- Sponsor
- LG Chem
- Start
- Apr 2018
- Primary completion
- Aug 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of gemigliptin in type 2 diabetes mellitus (T2DM) (5 arms), sponsored by LG Chem. Primary endpoints: Area under the plasma concentration versus time curve at Day 7 and Peak Plasma Concentration at Day 7. Status: unknown.
02
Drugs
gemigliptin
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT03565458.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03565458.